Kovitz Investment Group Partners LLC trimmed its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Rating) by 67.1% during the 4th quarter, HoldingsChannel reports. The fund owned 77,956 shares of the company’s stock after selling 158,814 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Takeda Pharmaceutical were worth $1,419,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Herold Advisors Inc. bought a new position in Takeda Pharmaceutical during the third quarter valued at about $33,000. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Takeda Pharmaceutical by 380.5% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,292 shares of the company’s stock valued at $38,000 after purchasing an additional 1,815 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $123,000. CoreFirst Bank & Trust grew its stake in shares of Takeda Pharmaceutical by 80.7% in the 3rd quarter. CoreFirst Bank & Trust now owns 9,346 shares of the company’s stock valued at $154,000 after purchasing an additional 4,173 shares during the period. Finally, Fisher Asset Management LLC bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $169,000. Hedge funds and other institutional investors own 2.63% of the company’s stock.
Shares of NYSE TAK traded down $0.16 during midday trading on Tuesday, hitting $14.54. The stock had a trading volume of 115,678 shares, compared to its average volume of 2,882,031. The company’s 50-day simple moving average is $14.88 and its 200 day simple moving average is $14.38. The firm has a market cap of $46.01 billion, a P/E ratio of 10.00 and a beta of 0.81. Takeda Pharmaceutical Company Limited has a fifty-two week low of $13.17 and a fifty-two week high of $17.56. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.37 and a quick ratio of 0.92.
Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group lowered Takeda Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Thursday, January 13th. Zacks Investment Research raised Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, January 26th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.00.
About Takeda Pharmaceutical (Get Rating)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines.
- Get a free copy of the StockNews.com research report on Takeda Pharmaceutical (TAK)
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.